Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases.  The Company is building a portfolio of compounds it believes could become pharmaceutical products.  Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Status Update

Q4 2025

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Exelixis Inc (EXEL US)

Status Update

Q4 2025

Stifel 2025 Healthcare Conference

Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Q3 2025

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)